Search PMCB
PharmaCyte Biotech, Inc.
Nasdaq · CIK 1157075
Last close0.4
Daily change-0.00 (-0.94%)
10 Years gain-99.28%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PMCB · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 0430
Fundamental
43.2Momentum
n/aAcceleration
0.0Confidence
62.0Annual Revenue16
Quarterly Revenue57
Annual CFO13
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality14.1 / 25
Capital Efficiency2.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 54.2475%.
ROIC declining · MEDIUMROIC declined by 11.8396 percentage points.
Key Metrics
Revenue Growth TTMn/aINSUFFICIENT_HISTORY
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-25.48%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y54.25%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 FY Apr 30, 2026 | $0.00 | $0.00 | -$6.85M | -$5.15M | n/a | n/a | n/a | n/a | -21.32% | 8.38M |
| 2026 FY Apr 30, 2025 | $0.00 | $0.00 | -$4.38M | -$2.98M | n/a | n/a | n/a | n/a | -50.05% | 7.33M |
| 2025 FY Apr 30, 2024 | $0.00 | $0.00 | -$8.52M | -$2.15M | n/a | n/a | n/a | n/a | n/a | 9.58M |
| 2024 FY Apr 30, 2023 | $0.00 | $0.00 | -$6.46M | -$3.79M | n/a | n/a | n/a | n/a | -111.23% | 19.49M |
| 2023 FY Apr 30, 2022 | $0.00 | $0.00 | -$4.39M | -$4.12M | n/a | n/a | n/a | n/a | -77.13% | 15.52M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $0.00 | sum latest 4 fiscal quarters Revenue | OK | 0001683168-26-007106, 0001683168-25-009259 |
| Revenue Growth TTM | n/a | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | INSUFFICIENT_HISTORY | 0001683168-26-007106, 0001683168-25-009259 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001683168-26-005836 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001683168-26-005836 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001683168-26-005836 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001683168-26-007106, 0001683168-25-009259 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| ROIC | -25.48% | NOPAT / Average Invested Capital | OK | 0001683168-26-007106, 0001683168-25-009259 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001683168-26-007106 |
| Current Ratio | 40.3x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.00 | Revenue / Diluted Shares | OK | 0001683168-26-007106, 0001683168-25-009259 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001683168-26-005836 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001683168-26-007106 |